Lisata Therapeutics Inc (LSTA) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Cost ... [Yahoo! Finance]
Lisata Therapeutics, Inc. (LSTA)
Company Research
Source: Yahoo! Finance
Research and Development Expenses: $2.5 million for Q3 2024, down 24.8% from $3.4 million in Q3 2023. General and Administrative Expenses: $2.8 million for Q3 2024, an increase of 8.1% from $2.6 million in Q3 2023. Net Loss: $4.9 million for Q3 2024, compared to $5.3 million in Q3 2023. Cash, Cash Equivalents, and Marketable Securities: Approximately $35.9 million as of September 30, 2024. Warning! GuruFocus has detected 1 Warning Sign with LSTA. Release Date: November 12, 2024 For the complete transcript of the earnings call, please refer to the full earnings call transcript Lisata Therapeutics Inc ( NASDAQ:LSTA ) reported a decrease in operating expenses by 10.5% compared to the same period last year, indicating effective cost management. The company has a strong cash position with approximately $35.9 million in cash, cash equivalents, and marketable securities, expected to fund operations into early 2026. Certepetide has shown promising potential in preclinical a
Show less
Read more
Impact Snapshot
Event Time:
LSTA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LSTA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LSTA alerts
High impacting Lisata Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
LSTA
News
- Lisata Therapeutics, Inc. (NASDAQ: LSTA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.MarketBeat
- Lisata Therapeutics Wins 2024 BioTech Breakthrough Award for ‘Specialized BioTherapeutics Company of the Year' [Yahoo! Finance]Yahoo! Finance
- Lisata Therapeutics Wins 2024 BioTech Breakthrough Award for ‘Specialized BioTherapeutics Company of the Year’GlobeNewswire
- Lisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswire
- Lisata Therapeutics and Valo Therapeutics Announce Preclinical Research Collaboration [Yahoo! Finance]Yahoo! Finance
LSTA
Earnings
- 11/12/24 - Beat
LSTA
Sec Filings
- 11/12/24 - Form 10-Q
- 11/12/24 - Form 8-K
- 10/2/24 - Form 4
- LSTA's page on the SEC website